Anti-Her-2 therapy which was mainly represented by trastuzumab can not only significantly inhibit tumor growth but also synergize with traditional cytotoxic chemotherapy to reduce recurrence risk of operable breast cancer patients by 46% and prolonged the OS (overall survival) of advanced breast cancer patients by 5-15 months [3]. This evidence concerns the gene ERBB2 and neoplasm.